Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anti‑epileptic (sodium channel modifier) presented as an injectable solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing treatment regimens.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anti‑epileptic drug indicated for the treatment of epilepsy, specifically partial‑onset seizures.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency. Focal epilepsy: used alongside other antiepileptics to improve seizure control. Refractory focal seizures: added when monotherapy is insufficient to achieve adequate control.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate gastrointestinal upset. - Headache: transient pain often relieved with rest. - Somnolence: increased sleepiness or fatigue. - Blurred vision: temporary visual disturbances. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: emergence of depressive thoughts. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: reduced breathing effort, especially with CNS depressants. - Anaphylaxis: acute allergic reaction with hives, swelling, or airway compromise. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing Lacosamide, clinicians should consider several safety aspects.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution and observe liver enzymes. Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. Concomitant CNS depressants: observe for additive sedation or respiratory effects. Pregnancy: risk category unknown; weigh maternal benefits against potential fetal risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may exacerbate PR‑interval prolongation. - Carbamazepine: can lower lacosamide plasma concentrations, reducing efficacy. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure and toxicity.

Moderate Interactions (Monitor Closely): - Other sodium‑channel blockers (e.g., phenytoin, lamotrigine): additive CNS effects may occur. - Opioids: heightened risk of respiratory depression and sedation.